Baxter International Inc. · NYSE:BAX
Baxter International — Shareholder Meeting (April 2020)
17 slides from Baxter International's shareholder meeting presentation, Apr 21, 2020
Slide 1: Annual Meeting Shareholder Engagement
Fall Shareholder Engagement August 2019 Baxter International Inc. April 2020 Annual Meeting Shareholder Engagement
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation includes forward-looking statements concerning Baxter’s financial results, business development activities, corporate governance goals, compensation program, COVID-19 response efforts and remediation efforts following the internal investigation related to fore
Slide 3: Executive Summary
Executive Summary Business Overview Leading global medical products company focused on transformative innovation to deliver smarter, more personalized care for patients and providers Addressing healthcare needs across the spectrum of care, our product settings include hospitals, homes, pharmacies, a
Slide 4: Committed Response To The COVID-19 Pandemic
Committed Response To The COVID-19 Pandemic Increasing Product Supply & Distribution Donating To Humanitarian Relief Expanding Employment Opportunities Protecting Employee Health and Safety Boosted capacity and production to address higher demand for: PrisMax and Prismaflex and associated solutions
Slide 5: Baxter: A Leading Medical Products Company
Baxter: A Leading Medical Products Company By Global Business Unit By Operating Segment Global Presence Continuous Innovation Industry-Leading Portfolio Operational Excellence ~50,000 Employees Worldwide 100+ Countries Where Baxter Products are Sold Manufacturing facilities in 20+ Countries Baxter’s
Slide 6: Our Strategy
Our Strategy Strengthen our portfolio and extend our impact through transformative innovation that spans prevention to recovery Top Quartile Goals Industry leading performance Best place to work Product safety and Quality Growth through innovation
Slide 7: Executing On Our Strategy: Recent Highlights
1Non-GAAP financial metrics referenced in this slide include operational sales growth and adjusted diluted EPS. A reconciliation to comparable U.S. GAAP measures is available at www.baxter.com. 2See www.baxter.com for original press releases with additional product information. 3Advancing American K
Slide 8: Continuing Momentum of Key Performance Metrics
Continuing Momentum of Key Performance Metrics1 1 Non-GAAP financial metrics referenced in this slide include operational sales growth, adjusted operating margin, and adjusted diluted EPS. A reconciliation to comparable U.S. GAAP measures is available at www.baxter.com. 2FY 2019 operational sales gr
Slide 9: Internal Investigation and Restatement Board Oversight
Internal Investigation and Restatement Board Oversight Executive Compensation Decisions In October 2019, the Company announced that it had commenced an internal investigation into certain intra-company transactions that impacted its previously reported non-operating foreign exchange gains and losses
Slide 10: Affirmative Steps to Enhance Internal Control
Affirmative Steps to Enhance Internal Control Discontinued use of historical exchange rate convention; using exchange rates determined in accordance with U.S. GAAP for purposes of measuring foreign currency transactions and remeasuring monetary assets and liabilities denominated in a foreign currenc
Slide 11: Director Skillsets Support Effective Oversight of Strategy
Director Skillsets Support Effective Oversight of Strategy CC = Compensation Committee; AC = Audit Committee; CGC = Corporate Governance Committee; QCT = Quality, Compliance & Technology Committee; asterisk denotes committee chair Jose (joe) almeida Chairman, President & CEO Former Chairman & CEO, C
Slide 12: Independent Board Leadership and Sound Board Practices
Independent Board Leadership and Sound Board Practices Heightened focus on refreshment and diversity has led to the appointment of two new independent Board members in 2019 as well as the hiring of an outside search firm to identify potential new Board members with medical / science, audit / interna
Slide 13: Strong Governance and Compensation Practices
Strong Governance and Compensation Practices 1 Unless the change in control results in the company no longer being a public company or the awards are not assumed by the successor entity. Governance Annual election of directors Active stockholder engagement program Majority voting standard in unconte
Slide 14: Executive Compensation Aligned with Strategic Priorities
Executive Compensation Aligned with Strategic Priorities CEO Pay Mix (2019) Salary Target Cash Bonus Target Stock Options Target PSUs 90% Variable/ “At-Risk” Pay Element Objectives Salary Provides a base level of competitive compensation Used to attract and retain executive talent Annual Incentive M
Slide 15: Restricted Stock Units, Performance Share Units and Stockholder Feedback
Restricted Stock Units (RSUs) Company did not issue any RSUs to named executive officers in 2019 Compensation Committee has not authorized and does not intend to authorize the issuance of any RSUs to any executive officers in 2020, except as may be required to retain and attract key personnel Perfor
Slide 16: Demonstrating Leadership In Corporate Social Responsibility
Demonstrating Leadership In Corporate Social Responsibility 1 “Complaint incidents” are the number of alleged product defects globally. “Medical device reports” are reports submitted to U.S. Food and Drug Administration (FDA) of certain medical device malfunctions, serious injuries or deaths associa
Slide 17: Recent Highlights
Recent Highlights A Recognized Top Employer and Outstanding Corporate Citizen Focusing On Inclusion and Diversity Expanding Access To Care Serving Our Communities Worldwide Reducing Our Environmental Footprint For more information on Baxter’s efforts to benefit our communities, employees, and stakeh
Baxter International — Shareholder Meeting (April 2020) on 6ix